Axonics Acquires Technology to Facilitate Easier and Faster Placement of Implantable Leads for Sacral Neuromodulation
April 24 2023 - 5:00AM
Business Wire
Axonics, Inc. (Nasdaq: AXNX), a global medical technology
company that is developing and commercializing novel products for
the treatment of bladder and bowel dysfunction, today announced the
acquisition of a lead placement solution from Radian, LLC that
complements Axonics’ existing sacral neuromodulation (SNM)
offering.
Physicians determine a patient’s eligibility for long-term SNM
therapy by performing an external trial or peripheral nerve
evaluation (PNE). The temporary lead that is placed during a PNE is
often done in the office setting without real-time imaging (i.e.,
fluoroscopy). Due to anatomic variability between patients,
locating the appropriate sacral foramen (closest to the desired
root of the sacral nerve) can be challenging without fluoroscopy
and can hinder physicians’ confidence in the procedure. The
acquired technology addresses this challenge with an elegant
solution comprising a software application and a hardware tool that
makes PNE lead placement easier, faster, and more accurate.
The technology has the potential to reduce procedure time and
facilitate a more accurate placement which, in turn, can increase
physicians’ confidence in the SNM procedure and drive increased
therapy adoption, utilization and permanent implant conversion
rates. With a standard x-ray image of a patient’s pelvis, a
physician can leverage the software to determine the optimal
location for needle entry and lead placement based on the patient’s
specific anatomy. The technology can readily be implemented into
existing clinical workflows as it takes only minutes to use and
requires minimal training.
Axonics has acquired the assets of Radian, LLC from Intermed
Labs for undisclosed terms. Axonics expects the product to receive
FDA clearance and be available on a commercial basis in
mid-2024.
“Since Axonics’ founding, our SNM development efforts have
focused on enhancing the physician and patient experience,” said
Raymond W. Cohen, chief executive officer of Axonics. “We expect
the Radian technology will improve patient comfort, increase
physician confidence and SNM access, simplify the learning curve
for physicians new to SNM, and increase PNE trial success rates,
which should ultimately result in more adults being treated with
our life-changing SNM therapy. We are confident that empowering
physicians with innovative technology and tools has the potential
to drive significant SNM market expansion in the years ahead.”
About Intermed Labs
Intermed Labs is an award-winning innovation lab and startup
studio that advances technological breakthroughs in health
technology. Intermed Labs works with talented physicians,
companies, and health systems to conceive, launch, and scale new
innovations to improve patient care. For more information, visit
www.intermedlabs.com.
About Axonics
Axonics is a global medical technology company that is
developing and commercializing novel products for adults with
bladder and bowel dysfunction. Axonics recently ranked No. 2 on the
2023 Financial Times ranking of the fastest growing companies in
the Americas and No. 4 on the 2022 Deloitte Technology Fast
500.
Axonics® sacral neuromodulation systems provide adults with
overactive bladder and/or fecal incontinence with long-lived, easy
to use, safe, clinically effective therapy. In addition, the
company’s best-in-class urethral bulking hydrogel, Bulkamid®,
provides safe and durable symptom relief to women with stress
urinary incontinence. In the U.S., moderate to severe urinary
incontinence affects an estimated 28 million women and fecal
incontinence affects an estimated 19 million adults. Axonics’
clinically proven products are offered at hundreds of medical
centers across the U.S. and abroad. Reimbursement coverage is well
established in the U.S. and is a covered service in most European
countries. For more information, visit www.axonics.com.
Forward-Looking Statements
Statements made in this press release that relate to future
plans, events, prospects or performance are forward-looking
statements as defined under the Private Securities Litigation
Reform Act of 1995. Words such as “plans,” “expects,” “believes,”
“anticipates,” “designs,” and similar words are intended to
identify forward-looking statements. While these forward-looking
statements are based on the current expectations and beliefs of
management, such forward-looking statements are subject to a number
of risks, uncertainties, assumptions and other factors that could
cause actual results to differ materially from the expectations
expressed in this press release, including the risks and
uncertainties disclosed in Axonics' filings with the Securities and
Exchange Commission, all of which are available online at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. Except as required by law, Axonics undertakes no obligation
to update or revise any forward-looking statements to reflect new
information, changed circumstances or unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230424005272/en/
Axonics contact: Neil Bhalodkar 949-336-5293
IR@axonics.com
Axonics (NASDAQ:AXNX)
Historical Stock Chart
From Apr 2024 to May 2024
Axonics (NASDAQ:AXNX)
Historical Stock Chart
From May 2023 to May 2024